ITreatOCD: Predicting the Efficacy of Internet-based Cognitive Behavioral Therapy in Obsessive-compulsive Disorder

NCT ID: NCT05906069

Last Updated: 2025-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-02

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the current study, the investigators will characterize obsessive-compulsive disorder (OCD) patients and healthy controls with a comprehensive clinical and neuroimaging assessment, focusing on the basic psychological processes related and on the neurobiological underpinnings of emotion regulation (ER). After a baseline assessment, the investigators will implement an internet-based cognitive behavioral therapy (iCBT) protocol and assess its efficacy on the modulation of ER and OCD severity. Specifically, the investigators will (1) examine to what extent the iCBT intervention modulates ER and the associated neurobiological mechanisms and (2) identify candidate biomarkers of successful treatment response.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sixty patients and sixty controls will be recruited at Hospital de Braga, Braga, Portugal (sample size estimated based on a previous systematic review). A power analysis indicated that a sample of 24 individuals per group is adequate to detect an effect size of d=.89, with a Type I error of .05 and a statistical power of .85. A final sample of 30 individuals was defined to account for a 20% dropout rate during the intervention.

All participants will be assessed with a comprehensive psychological and clinical characterization. Following the baseline assessment, OCD patients will be randomly allocated to the intervention (iCBT intervention) or the control group (waiting list). The iCBT intervention will consist of a structured program comprising 10 modules with text and video content, as well as 3 videoconferencing psychotherapy sessions. After the intervention/waiting list, patients will be re-assessed with the clinical and psychological assessment.

In order to characterize the patterns of brain activation in OCD patients during an emotion regulation task in comparison to healthy controls and to identify potential neurobiological markers of symptoms' improvement, a multimodal neuroimaging assessment will also be performed. The task encompasses the presentation of pictures (fearful, neutral and OCD-related stimuli) under two conditions: the instruction to view the pictures naturally ('observe'); or to apply cognitive reappraisal techniques to decrease any negative affective state caused by the stimuli ('regulate'). Fear and OCD-related pictures are presented during both conditions; neutral pictures only during 'observe'. After each stimulus, the level of distress will be assessed by a self-report rating scale.

In the baseline assessment, brain activation patterns (with whole-brain and region of interest approaches) will be compared between OCD and healthy controls in both task conditions. After intervention, emotion regulation ability and the underlying neurobiological mechanisms will be compared between the 'intervention' and 'waiting list' groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obsessive-Compulsive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

OCD patients will be randomly allocated into two groups - iCBT group (experimental group) and wait list group (comparator control group). The experimental group will receive a 14-week iCBT intervention program and the wait list group will receive the same intervention but at a later time.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
The psychologist performing the assessment of the main psychometric outcomes will be blind to the group allocation of each participant.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

iCBT intervention

Participants will enroll in an internet-based cognitive behavioral program during 14 weeks. The program comprises 10 modules and three videoconferencing psychotherapy sessions.

Group Type EXPERIMENTAL

ICBT

Intervention Type BEHAVIORAL

The intervention will consist in a structured internet-based intervention with 10 modules that will combine cognitive-behavioral techniques to improve obsessive-compulsive symptoms as well as the emotion regulation ability.

Wait list

Participants will be enrolled in the iCBT program after 14 weeks

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ICBT

The intervention will consist in a structured internet-based intervention with 10 modules that will combine cognitive-behavioral techniques to improve obsessive-compulsive symptoms as well as the emotion regulation ability.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary diagnosis of current OCD according to the fifth Diagnostic and Statistical Manual of Mental Disorders
* YBOCS score ≥ 16
* Psychotropic medication, if stable for at least 2 months prior to inclusion and if the dosage is maintained thoughout the study
* Have the resources to access the online intervention (internet access; computer or tablet)

Exclusion Criteria

* MRI contraindications
* Prior medical history of neurological disorders or traumatic brain injury
* Having performed CBT treatment for OCD in the last 2 years
* Undergoing any psychological treatment
* Suicidal ideation
* Current alcohol or drug abuse
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital de Braga

OTHER

Sponsor Role collaborator

ICVS - Life and Health Sciences Research Institute

UNKNOWN

Sponsor Role collaborator

Clinical Academic Center (2CA)

UNKNOWN

Sponsor Role collaborator

Associação Centro de Medicina P5 (ACMP5)

UNKNOWN

Sponsor Role collaborator

Pedro Morgado

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pedro Morgado

Assistant Professor, M.D., Ph.D.

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pedro Morgado, M.D, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Life and Health Sciences Research Institute, School of Medicine, University of Minho

Braga, Gualtar, Portugal

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Portugal

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pedro Morgado, M.D, Ph.D.

Role: CONTACT

+351 253 604 931

Mafalda Sousa, M., Sc.

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pedro Morgado, M.D, Ph.D.

Role: primary

00351 253 604 931

Mafalda Sousa, M. Sc.

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

iTREATOCD_ICVS2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.